13/07/2020
We are delighted to confirm that our President & CEO, Dr. IM Bennani-Baiti, will be leading the panel discussion on “Combination therapies vs monotherapies” at the upcoming Epigenetic Therapeutic Targets Summit, taking place online on July 28, 2020.
The Summit is the very first and only virtual meeting which specifically looks at the new applications and challenges of progressing epigenetic drug candidates through early translational studies and clinical trials, such as developing potent and highly selective inhibitors with minimal off-target drug effects.
Dr. Bennani-Baiti is joining a stellar line-up of speakers from STORM therapeutics, Oryzon Genomics, Incyte, Epizyme, 4SC, GSK, Imago Biosciences, Omega Therapeutics, Genentech, Resverlogix Corp., Accent Therapeutics and more.
The Epigenetic Therapeutic Targets Summit is a rare opportunity to meet and hear from the world-class experts who are at the forefront of epigenetic research. We are looking forward to meeting you online on July 28.
You can find a full event guide available https://epigenetic-targets.com/whats-on/full-event-guide/
To register – visit Summit website.